Fosun Pharma (600196.SH): Multiple drugs included in the National Medical Insurance Catalog

Zhitong Finance APP news, Fosun Pharma (600196.SH) issued an announcement that, according to the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2026)" released on November 14, 2026 by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, multiple marketed products of the company and its controlled subsidiaries/units have been included for the first time, have had remarks-related information adjusted, or have been transferred from negotiated drugs to routine catalog management. Among them, serplulimab injection has been included for the first time, fovitinib citrate capsules and luvo-metinib tablets have added reimbursed indications, and anti-human T-cell rabbit immunoglobulin has had payment restrictions relaxed. Netupitant and palonosetron capsules and maribavir tablets have been transferred from negotiated drugs to routine catalog management.